Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-30 @ 9:15 PM
Study NCT ID:
NCT07456995
Status:
COMPLETED
Last Update Posted:
2026-03-09
First Post:
2026-02-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Mandibular Posterior Zirconia Crowns With Different Ti-Base Surface Treatments.
Sponsor:
October University for Modern Sciences and Arts
Organization:
Study Overview
Official Title:
Clinical Evaluation of Mandibular Posterior Screw-retained Zirconia Crown With Various Ti-Base Abutment Surface Treatments: Randomized Controlled Clinical Trial
Status:
COMPLETED
Status Verified Date:
2026-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RCT
Brief Summary:
This clinical trial evaluates how different surface treatments on a metal base (Ti-Base) affect the success of dental crowns on implants. Patients receiving a zirconia crown for a missing lower back tooth are divided into three groups: one group receives no special treatment on the metal base, one group receives a silica coating, and the third receives both a silica coating and a chemical primer. The study monitors these crowns for one year to see which treatment best prevents the crown from coming loose or breaking, while also checking the health of the surrounding gums.
Detailed Description:
This is a three-arm, parallel-group, superiority randomized controlled trial. The research question addresses the impact of silica coating (CoJet Sand) and primer (Z-Prime Plus) on the survival of mandibular posterior screw-retained zirconia crowns.+3The primary intervention involves treating the titanium base (Ti-Base) abutment surface using 30-mm $SiO\_2-Al\_2O\_3$ particles at 2.0 bar pressure. The three groups are:Group I (Control): No surface treatment.Group II: Tribochemical silica coating alone.Group III: Tribochemical silica coating followed by Z-Prime Plus application.Survival is evaluated using modified United States Public Health Service (USPHS) criteria at baseline, 6 months, and 12 months. Biological health is assessed via the modified plaque index (mPI) and modified Sulcus Bleeding Index (mSBI).
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: